Zenith Technologies appoints MES lead
James O’Brien will lead the company's manufacturing execution system business to its next phase of growth.
Global life science technology firm, Zenith Technologies, has appointed James O’Brien to lead its manufacturing execution system (MES) business to its next phase of growth.
During the past 5 years, Zenith Technologies has strategically grown its MES offering globally to meet growing demand for technology-based manufacturing efficiency programs in the life science sector.
In his role as MES business unit lead, James will use his background in software development, consultancy and technology implementation to continue to develop Zenith Technologies as a world leader in the provision of MES solutions and services to the life science industry.
Zenith Technologies assists pharmaceutical and medical device manufacturers with the implementation of MES solutions, providing on-the-ground support. James will be focused on forming further collaborations in the industry to support life science companies with the transition to MES and automated systems.
Commenting on the appointment, Jim Lehane, director at Zenith Technologies, said: “James has worked with us as a senior MES engineer for a number of years, supporting some of the world’s leading pharmaceutical companies with global automation projects. In his new role as MES business unit lead, James will drive Zenith Technologies forward to further success in the US and Europe, leveraging our global presence, skilled engineers and world-class implementation and support services.”
James’ appointment comes as MES technology is being adopted by the life science industry at a faster rate than any other vertical market. To support demand, the firm recently announced a partnership with MES software provider Werum IT Solutions.
Jim continued: “It’s an exciting time for our company, as pharmaceutical and medical device manufacturers are recognising the benefits of MES and adoption is increasing at a steady rate. In particular, we are experiencing increasing demand in the US market, which has led us to open two new offices in Oakland and San Diego.”
Based in Bluebell, PA, James will lead Zenith Technologies’ team of engineers in 16 offices globally to support clients with their manufacturing enterprise solution needs.
He said: “MES technology can dramatically improve productivity during manufacturing, however there are a number of challenges associated with its implementation. It is our goal to assist companies with the transition to MES systems so they can realise the benefits with minimal disruption to their operations.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.